Evidence map›Paper›PMID 33997889›Full record

ArticleGlycobiology2021

A minimal sequon sufficient for O-linked glycosylation by the versatile oligosaccharyltransferase PglS.

Cory J Knoot, Lloyd S Robinson, Christian M Harding

Open access · hybridAbstract read
In one paragraph

Article in Glycobiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. CRISPRi-Mediated Silencing ofJournal of proteome research · 2023
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Cory J KnootVaxNewMo, 4340 Duncan Ave., Suite 202, St. Louis, MO 63110, USA.
Lloyd S RobinsonVaxNewMo, 4340 Duncan Ave., Suite 202, St. Louis, MO 63110, USA.
Christian M HardingVaxNewMo, 4340 Duncan Ave., Suite 202, St. Louis, MO 63110, USA.

Funding

Towards a New Generation of Glycoengineered Pneumococcal Bioconjugate VaccinesR44AI131742 · NIAID · VAXNEWMO, LLC · PI HARDING, CHRISTIAN · 2020 to 2022
$2.9M
NIAID NIH HHS R44 AI131742NIAID NIH HHS R44AI131742
6 · The paper itself

Abstract

Bioconjugate vaccines, consisting of polysaccharides attached to carrier proteins, are enzymatically generated using prokaryotic glycosylation systems in a process termed bioconjugation. Key to bioconjugation are a group of enzymes known as oligosaccharyltransferases (OTases) that transfer polysaccharides to engineered carrier proteins containing conserved amino acid sequences known as sequons. The most recently discovered OTase, PglS, has been shown to have the broadest substrate scope, transferring many different types of bacterial glycans including those with glucose at the reducing end. However, PglS is currently the least understood in terms of the sequon it recognizes. PglS is a pilin-specific O-linking OTase that naturally glycosylates a single protein, ComP. In addition to ComP, we previously demonstrated that an engineered carrier protein containing a large fragment of ComP is also glycosylated by PglS. Here we sought to identify the minimal ComP sequon sufficient for PglS glycosylation. We tested >100 different ComP fragments individually fused to Pseudomonas aeruginosa exotoxin A (EPA), leading to the identification of an 11-amino acid sequence sufficient for robust glycosylation by PglS. We also demonstrate that the placement of the ComP sequon on the carrier protein is critical for stability and subsequent glycosylation. Moreover, we identify novel sites on the surface of EPA that are amenable to ComP sequon insertion and find that Cross-Reactive Material 197 fused to a ComP fragment is also glycosylated. These results represent a significant expansion of the glycoengineering toolbox as well as our understanding of bacterial O-linking sequons.

Indexed as

HexosyltransferasesAmino Acid SequenceFimbriae ProteinsGlycosylationMembrane Proteinsdolichyl-diphosphooligosaccharide - protein glycotransferaseFimbriae ProteinsHexosyltransferasesMembrane Proteinsbioconjugationglycoconjugate vaccineO-glycosylationoligosaccharyltransferasesequon

Identifiers

PMID33997889
PMCPMC8457361
OpenAlexW3162002312

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.